The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.
In retrospect—even though Army life was not for me—going to France was a unique opportunity for a young man to gain perspective on the culture of Western Europe. With my 2-year “vacation” at an end, I was ready to focus on my future in ophthalmology.
As part of Ophthalmology Times’ coverage of the 14th EURETINA Congress in London this week, Group Content Director Mark L. Dlugoss writes this blog.
The Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Dosing has commenced for the first patients enrolled in Aerie Pharmaceuticals’ phase III registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension.